Experimental coronavirus treatment remdesivir delivers 'positive data' in trial, says developer Gilead

The experimental coronavirus treatment remdesivir has generated “positive data” in a trial of the antiviral organized by the National Institute of Allergy and Infectious Diseases (NIAID), according to developer Gilead Sciences.

Leave a comment

Your email address will not be published. Required fields are marked *